Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IM Cannabis Corp. (IMCC)
USD0.15
+0.00 (+2.83%)
IL NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
Kibbutz Glil Yam 4690500
Tel Aviv, IL
Tel Aviv, IL
CEO
Oren Shuster
Website
imcannabis.com
IPO
2020-05-20
CIK 1792030 ISIN CA44969Q4060
Also trades on
Canadian Securities Exchange · IMCC.CN (CAD)
NASDAQ Capital Market · IMCC (USD)
Description
IM Cannabis Corp. specializes in the cultivation, production, and provision of medicinal cannabis goods throughout international markets such as Israel, Germany, and Canada. The company offers a range of cannabis products, including flowers and specifically formulated cannabis extracts, marketed under its IMC brand. Furthermore, it supplies dried flower, pre-rolled products, and compressed hashish via its WAGNERS and Highland Grow labels. IM Cannabis Corp. serves a broad customer base, addressing the needs of both medical patients and adult recreational consumers. Its corporate headquarters are located in Tel Aviv-Yafo, Israel.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.15
+0.00 (+2.83%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
1.98
Float Shares
953.0K
Free Float %
30.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.07% | +13.83% | +1.62% | -57.65% | -84.18% | -79.28% | -95.35% | -95.51% | -99.89% | -94.17% | -94.17% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
0.15
Ratings Trend (MoM)
0% Bullish
| Rating | 2025-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-15.77
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+1.3% Q1'26: -49.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+40.8% ★ Q1'26: -537.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.6% Q1'26: -6.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-16.3% Q1'26: -19.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-89.7% Q1'26: -55.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+80.5% Q1'26: +92.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-2.34× Q1'26: -4.35× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
9.07M
est: 8.25M (+10.0%)
|
15.89M
est: 18.48M (-14.0%)
|
34.05M
est: 52.26M (-34.8%)
|
54.34M
est: 76.20M (-28.7%)
|
48.80M
est: 50.84M (-4.0%)
|
54.03M
est: 55.28M (-2.3%)
|
54.73M
est: 74.49M (-26.5%)
|
86.11M
86.11M – 86.11M
+15.6% YoY
|
| EBITDA |
-6.02M
est: -1.22M (-393.9%)
|
-7.04M
est: -2.73M (-157.6%)
|
6.24M
est: -7.72M (+180.8%)
|
-16.76M
est: -11.26M (-48.8%)
|
-2.79M
est: -7.51M (+62.9%)
|
-6.14M
est: -4.68M (-31.4%)
|
-6.95M
est: -6.30M (-10.2%)
|
-7.28M
-7.28M – -7.28M
-15.6% YoY
|
| EBIT |
-6.62M
est: -1.98M (-233.8%)
|
-7.97M
est: -4.45M (-79.2%)
|
509.0K
est: -12.57M (+104.0%)
|
-24.09M
est: -18.33M (-31.4%)
|
-5.79M
est: -12.23M (+52.7%)
|
-8.33M
est: -9.55M (+12.8%)
|
-8.90M
est: -12.87M (+30.8%)
|
-14.87M
-14.87M – -14.87M
-15.6% YoY
|
| Net Income |
-7.29M
|
-28.70M
|
-17.76M
est: -48.52M (+63.4%)
|
-188.89M
est: -323.12M (+41.5%)
|
-9.50M
est: -8.40M (-13.0%)
|
-10.59M
est: -23.13M (+54.2%)
|
-11.32M
est: -1.85M (-513.2%)
|
-1.87M
-1.87M – -1.87M
-1.2% YoY
|
| SGA |
10.34M
est: 5.23M (+97.7%)
|
18.71M
est: 11.72M (+59.7%)
|
28.09M
est: 33.14M (-15.2%)
|
28.91M
est: 48.32M (-40.2%)
|
19.03M
est: 32.23M (-41.0%)
|
13.28M
est: 24.64M (-46.1%)
|
12.94M
est: 33.21M (-61.0%)
|
38.39M
38.39M – 38.39M
+15.6% YoY
|
| EPS |
-2.28
|
-7.45
|
-5.71
est: -20.66 (+72.4%)
|
-76.80
est: -137.55 (+44.2%)
|
-4.45
est: -3.58 (-24.4%)
|
-4.51
est: -5.46 (+17.3%)
|
-2.67
est: -0.44 (-513.2%)
|
-0.44
-0.44 – -0.44
-1.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-4.83M
OE per share TTM
-0.96
Owner's Yield
-282.88%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
29.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
9
Total invested
10.5K
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Oren Shuster | 9.67M | 14.14% | 9.66M | 1.5K | 9.66M | 10.00 | CO | Israel | 2022-02-14 | ↗ |
| 2 | Rafael Rifat Gabay | 8.14M | 11.98% | 8.13M | 1.5K | 8.13M | 1.5K | IN | Israel | 2022-02-16 | ↗ |
| 3 | Luminera Derm Ltd.00-0000000 | 1.51M | 14.09% | 1.51M | — | 1.51M | — | CO | Israel | 2023-02-21 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
9
-4 vs prev Q
New positions
0
Closed positions
4
Increased
1
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | HIDDEN COVE WEALTH MANAGEMENT, LLC | 14.3K +— (+0.0%) | 5.3K -14.6K (-73.4%) | 0.34% +0.000 pp | 0.00% -0.010 pp | USD1.92 -80.7% | 3 qtrs — |
| 2 | BANK OF MONTREAL /CAN/ | 11.9K +4.0 (+0.0%) | 4.4K -12.1K (-73.4%) | 0.28% +0.000 pp | 0.00% +0.000 pp | USD2.38 -84.5% | 7 qtrs — |
| 3 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 1.9K -3.0 (-0.2%) | 701.00 -1.9K (-73.4%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD2.35 -84.3% | 7 qtrs — |
| 4 | NATIONAL BANK OF CANADA /FI/ | 103.00 +— (+0.0%) | 37.00 -104.0 (-73.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.53 -75.8% | 7 qtrs — |
| 5 | ADVISOR GROUP HOLDINGS, INC. | 33.00 +— (+0.0%) | 12.00 -34.0 (-73.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.73 -78.6% | 6 qtrs — |
| 6 | TD WATERHOUSE CANADA INC. | 12.00 +— (+0.0%) | 4.00 -12.0 (-75.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.67 -77.8% | 7 qtrs — |
| 7 | BRYN MAWR TRUST CO | 9.00 +— (+0.0%) | 3.00 -10.0 (-76.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.33 -84.1% | 7 qtrs — |
| 8 | UBS GROUP AG | 3.00 +— (+0.0%) | 1.00 -3.0 (-75.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.33 -84.1% | 4 qtrs — |
| 9 | GROUP ONE TRADING, L.P. | 2.00 +— (+0.0%) | 1.00 -2.0 (-66.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -81.5% | 7 qtrs — |
| 10 | MORGAN STANLEY | — -100.0 (-100.0%) | — -139.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 11 | HERON BAY CAPITAL MANAGEMENT | — -25.9K (-100.0%) | — -36.0K (-100.0%) | 0.00% -0.610 pp | 0.00% -0.007 pp | USD— | 4 qtrs SOLD |
| 12 | DRW SECURITIES, LLC | — -23.1K (-100.0%) | — -32.1K (-100.0%) | 0.00% -0.544 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 13 | ADVISORSHARES INVESTMENTS LLC | — -102.1K (-100.0%) | — -141.9K (-100.0%) | 0.00% -2.409 pp | 0.00% -0.024 pp | USD— | 7 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-93.7K
Shares Outstanding
3.09M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Oren Shuster | Chief Executive Officer & Executive Director | 381.9K | male |
| Richard Balla | Chief Executive Officer of Adjupharm | 230.1K | male |
| Eyal Fisher | Chief Executive Officer of the IMC Holdings | 215.6K | male |
| Asi Levi | Chief Financial Officer | 160.1K | male |
| Advocate Michal Lebovitz Nissimov | General Counsel & Secretary | 138.7K | — |
| Anna Taranko | Director Investor & Public Relations | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMCC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
